

Curriculum Vitae

ORCID ID:0001-5014-430X

LOREDANA CIFALDI

Personal information

Name **Loredana Cifaldi**
Address Via Pomezia, 44/A/6 00183 Rome-Italy
Telephone(s) Mobile: 0039 3382396587
E-mail cifaldi@med.uniroma2.it
loredana.cifaldi@opbg.net
loredana_cifaldi@yahoo.it
Nationality Italian
Date of birth June 4th 1974

Iscrizione all'Albo dei Biologi, Elenco speciale: Cod EA_020119.

Occupation or position held

Assistant professor (tenure track) RTDb at University Tor Vergata in Rome
July 21st 2020-presently
Researcher at Bambino Gesù Children Hospital in Rome (research contract)
January 2007-2023

Main activities and responsibilities

The majority of projects of Dr Cifaldi L. aims to develop new NK cell-based Immunotherapies

Biosketch

Dr Cifaldi has a strong knowledge and experimental background in tumor immunology and in particular in NK cell activities in mice and human. Her studies have been recognized at the international level with publications in peer reviewed journals.

1. Anti-tumor efficacy of low doses of IL-2 in a murine model of breast cancer

Dr Cifaldi demonstrated that the administration of low doses of IL-2 in HER-2/neu mice, a murine model of breast cancer, inhibits mammary carcinogenesis (Cifaldi L. et al., Cancer Research 2001). She also demonstrated that IL-2-activated lymphocytes affect tumor genetic programs (Cavallo F. et al., Cancer Research 2001).

2. Antagomir 17-5p-mediated inhibition of Neuroblastoma growth in vivo

Dr Cifaldi has been involved in a project to identify a new therapeutic approach for high risk neuroblastoma based on the use of antagomir 17-5p in xenograft murine models. Dr Cifaldi performed all the *in vivo* experiments thanks to the experience in animal manipulation acquired during a post-doc periods at the Pasteur Institute. Her intellectual and *in vivo* experimental contributions in mouse model of neuroblastoma conferred high prestige to published data (Fontana et al. PlosOne 2008), a paper that currently counts 331 citations as reported by Scopus.

3. Role of the Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) in NK cell-mediated antitumor response

The strong knowledge on NK cells allowed Dr Cifaldi to provide the main intellectual and technical tools in order to study the functional link between ERAP1 and NK cells in murine model (Cifaldi L. et al., Cancer Research 2011) and in human (Cifaldi L. et al., Cancer Research 2015). Specifically, she demonstrated that ERAP1 regulates NK cell functions and its inhibition may be exploited to improve the efficacy of NK cell-based approaches for cancer immunotherapy.

4. Role of IL-6 on NK cell-mediated functions

Dr Cifaldi demonstrated the role of IL-6 on NK cell functions in the pathogenesis of macrophage activation syndrome (Cifaldi L. et al., Arthritis Rheumatology 2015). Due to the discovery of the impact of IL-6 on the immune response in the context of Sars-CoV-2 infection, this paper now counts 162 citations as reported by Scopus.

5. Correlation between MYCN and the expression of ligands for NK cell-activating receptors in neuroblastoma

In 2015, Dr Cifaldi established her group focusing on the development of a new NK cell-based immunotherapies for high-risk neuroblastoma (NB). She demonstrated that MYCN acts as an immunosuppressive oncogene that negatively regulates the expression of ligands for NK cell-activating receptors, thus representing a biomarker to predict the susceptibility of NB to NK cell-mediated immunotherapy (Brandetti E. & Veneziani I. et al., Oncoimmunology 2017). Moreover, she demonstrated that drugs currently used in clinical treatment of NB (Veneziani I. et al. J Immunol Res 2018) as well as BET domain inhibitor JQ1 have negative immunomodulatory effects on NB cells in terms of induction of ligands for NK cell activating receptors (Veneziani I. et al. Oncotarget 2019). She discovered that the rescue of p53 function mediated by Nutlin-3a induces the expression of ligands for NK cell-activating receptors by rendering NB cells more susceptible to NK cell recognition and function (Veneziani I. et al. Cancer Immunology Research 2021). Recently, she demonstrated that the transfection with NF- κ B p65 subunit and the treatment with cytokines such as IFN γ and TNF α induce the expression of FAS and PVR on NB cells, thus enhancing the NK cell-mediated recognition and apoptosis of NB cells. Interestingly, she demonstrated that loss of *FAS* and *PVR* genes correlates with low survival of NB patients, thus identifying new prognostic biomarkers of NB (Brandetti E. et al. Cancers 2021).

6. DNAM-1-CAR-NK cells

In 2022, Dr Cifaldi published data on the design and *in vitro* functional activity of novel, never-before-reported, DNAM-1-chimeric receptor-engineered NK cells, to propose an innovative NK cell-based cancer immunotherapy. She generated human NK cells expressing either the full length DNAM-1 receptor or three different DNAM-1-based chimeric receptor that provide the expression of DNAM-1 fused to a costimulatory molecule such as 2B4 and CD3 ζ chain. Upon transfection into primary human NK cells isolated from healthy donors, she evaluated the surface expression of DNAM-1 together with that of other NK cell receptors and, as a functional readout, she assessed the extent of degranulation, cytotoxicity and the production of IFN γ and TNF α in response to human leukemic K562 cell line. Furthermore, both LA-N-5 and SMS-KCNR NB cell lines pretreated with Nutlin-3a were significantly more susceptible to DNAM-1-engineered NK cells than NK cells transfected with the empty vector. These results provide a proof-of-concept suggesting that the use of DNAM-1-chimeric receptor-engineered NK cells may represent a novel therapeutic approach of cancer immunotherapy (Focaccetti C. & Benvenuto M. et al. Frontiers in Immunology 2022).

Research activities

<u>Jan 2007-Jul 2023</u>	Research contract Project title: Studies of NK cells in Neuroblastoma and other Pediatric diseases Bambino Gesù Children's Hospital, Department of Paediatric Haematology/Oncology of Prof. Franco Locatelli; Academic Department of Pediatrics (DPUO) of Prof. Paolo Rossi.
<u>Febr-Dec 2006</u>	Research fellow Project title: Role of NK cells in the skin of Dermatitis patients. Istituto Dermopatico dell'Immacolata IRCCS in Rome, Laboratory of Immunology and Allergology of Dr Andrea Cavani.
<u>Dec 2004-Nov 2005</u>	Fondation de la Recherche Medical (FRM) fellowship Project title: Study on the homeostatic control of mature NK cells in mice. Pasteur Institute in Paris, Unité Cytokines et Développement Lymphoïde Laboratory of Immunology of Dr James Di Santo
<u>Sept 2003-Nov 2004</u>	Fondazione Pasteur-Cenci Bolognetti fellowship Project title: Cdc42/Wasp pathway in the control of NK cell cytotoxic activity. "La Sapienza" University in Rome, Laboratory of Immunology of Prof. Angela Santoni.
<u>Sept 2001-Aug 2003</u>	University Research Contract Project title: Role of the tyrosin kinase Pyk2 in the control of human Natural Killer cell functions "La Sapienza" University in Rome, Laboratory of Immunology of Prof. Angela Santoni
Education and training	
<u>Jan 1998-Jul 2001</u>	Specialist in Clinical Biochemistry, School of Clinical Biochemistry
Principal subjects	Projects: Study of Tumor Genetic Program Influenced by Interleukin 12-activated Lymphocytes; A Light, Nontoxic Interleukin 12 Protocol Inhibits HER-2/neu Mammary Carcinogenesis in BALB/c Transgenic Mice with Established Hyperplasia. Research activity in Biochemistry; Quantity determination of Urinary Trypsin Inhibitor UTI, a new marker of Alzheimer disease.
Name and address of research institute	University of Torino Laboratory of Immunology of Prof. Guido Forni; University of Camerino Laboratory of Prof. Evandro Fioretti.

September 1998

Licence for Biologist profession

July 1997

Degree in Biology, vote 110/110, University of Camerino

Awards/Honors

Research Grants:

Ministero della Salute – Young Researcher (under 40years)/Giovani Ricercatori

- **Principal Investigator (PI)**

Title: Natural Killer cell-based immunotherapy for high-risk Neuroblastoma: pharmacological treatment to efficiently improve the expression of activating ligands.

November 2014-October 2018

Project code: GR-2011-02352151

- **Collaborator (PI Dr Giusi Prencipe)**

Title: IFNgamma as a potential therapeutic target in secondary HLH.

November 2014-October 2017

Project code: GR-2011-02347874

PI: Ministero della Salute-Ricerca Corrente 5 X 1000 grant 2020

Title: Caratterizzazione fenotipica e funzionale di alto profilo delle cellule Natural Killer in pazienti in età pediatrica affetti da infezioni virali come CMV e EBV finalizzata al disegno di nuove immunoterapie antivirali nelle patologie pediatriche: un nuovo approccio di medicina personalizzata nella interpretazione dei fenotipi malattia

Collaborator: PRIN 2020, settore ERC: LS3, 20205HZBP8 (PI Michele Milella)

Title: Gene/environment interactions in breast and thyroid cancers: defining the biological role of and actioning endocrine disruptors and lifestyle to develop rational therapeutic/preventive interventions (Asteroid)

Congress oral presentations

- ECI 2018, September 2018, Amsterdam, The Netherland
- SIICA 2017, May 2017, Bari, Italy
- SIICA 2003 May 2003, Verona, Italy

National Scientific Qualifications (Abilitazione Scientifica Nazionale)

for Associate Professor (fascia II) in:

- Patologia Generale e Patologia Clinica -06/A2
- Scienze delle Professioni Sanitarie e delle Tecnologie Mediche Applicate-06/N1

Academic position

Assistant professor in General Pathology-(tenure track) RTDb, University of Rome "Tor Vergata"

Idoneità per la selezione pubblica per il reclutamento di un ricercatore tipo b, ai sensi dell'art. 24, comma 3, lettera b), della legge 30 dicembre 2010 n. 240, presso il Dipartimento di Scienze Cliniche e Medicina Traslazionale, Università di Roma "Tor Vergata", Settore concorsuale 06/A2, Settore Scientifico Disciplinare MED/04. Anno 2019.

Teaching activities and PhD supervision

Tutor for PhD students:

- Dr Elisa Brandetti, PhD student of Dottorato di Ricerca in Immunologia e Biotecnologie Applicate, 2016-2018, Università di Roma "Tor Vergata"
- Dr Irene Veneziani, PhD student of Dottorato di Ricerca in Scienze Immunologiche Ematologiche e Reumatologiche, 2015-2017, Università di Roma "La Sapienza"

Tutor of Degree in Biotechnology (Tor Vergata University)

Tutor of Degree in Scienze e Tecniche dello Sport (Tor Vergata University)

Reviewer for indexed journals

- OncoImmunology
- AutoImmunity
- PlosOne
- Gene
- Journal of Stem Cell Research & Therapeutics
- ACAMC
- British journal of Cancer
- Innate Immunity
- OncoTarget and Therapy
- Scientific Reports
- Frontiers in Immunology
- Cancers
- JACI

Editorial contributions

- **Frontiers in Immunology**: editor for a Research Topic titled: *Molecular strategies aimed to boost NK cell-based Immunotherapy of cancer*
- **International Journal of Molecular Sciences** - guest editor for a Special Issue titled: *The Effect of Dietary Factors on Cancer 3.0*

Publications (*corresponding author)

1. Different outcome of targeting ERN1/IRE1 alpha and EIF2AK3/PERK in NSG mice engrafted with primary effusion lymphoma.
Arena A, Romeo MA, Focaccetti C, Anastasiadou E, Trivedi P, **Cifaldi L**, Gilardini Montani MS, Benedetti R, Santarelli R, Gonnella R, Benvenuto M, Marchese C, Masuelli L, Bei R, Cirone M. Br J Haematol. 2023 Feb 12. doi: 10.1111/bjh.18688. PMID: 36775956
2. Recent finding on the impact of ErbB receptor status on prognosis and therapy of head and neck squamous cell carcinoma
Palumbo C, Benvenuto M, Focaccetti C, Albonici L, **Cifaldi L**, Rufini A, Nardozi D, Angiolini V, Bei A, Masuelli L, and Bei R. Frontiers in Medicine, 2023 Feb 2;10:1066021. Doi:10.3389/fmed.2023.1066021. PMID: 36817764.
3. DNAM-1-chimeric receptor-engineered NK cells, combined with Nutlin-3a, more effectively fight neuroblastoma cells *in vitro*: a proof-of-concept study.
Focaccetti C, Benvenuto M, Pighi C, Vitelli A, Napolitano F, Cotugno N, Fruci D, Palma P, Rossi P, Bei R, **Cifaldi L***. Front Immunol. 2022 Jul 28;13:886319. doi: 10.3389/fimmu.2022.886319. eCollection 2022.PMID: 35967339
4. Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy.
D'Amico S, Tempora P, Melaiu O, Lucarini V, **Cifaldi L**, Locatelli F, Fruci D. Front Immunol. 2022 Jul 22;13:948297. doi: 10.3389/fimmu.2022.948297. eCollection 2022.PMID: 35936007
5. Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.
Bei R, Benvenuto M, Focaccetti C, Fazi S, Moretti M, Nardozi D, Angiolini V, Ciuffa S, **Cifaldi L**, Carrano R, Palumbo C, Miele MT, Bei R, Barillari G, Manzari V, De Smaele E, Modesti A, Masuelli L. J Transl Med. 2022 Jun 25;20(1):286. doi: 10.1186/s12967-022-03490-9.PMID: 35752861
6. ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function.
D'Amico S, D'Alicandro V, Compagnone M, Tempora P, Guida G, Romania P, Lucarini V, Melaiu O, Falco M, Algeri M, Pende D, **Cifaldi L**, Fruci D. Front Immunol. 2021 Nov 30;12:778103. doi: 10.3389/fimmu.2021.778103. eCollection 2021.PMID: 34917091
7. Polyphenols affect the humoral response in cancer, infectious and allergic diseases and autoimmunity by modulating the activity of T_H1 and T_H2 cells.
Benvenuto M, Focaccetti C, Ciuffa S, Fazi S, Bei A, Miele MT, Albonici L, **Cifaldi L**, Masuelli L, Bei R. Curr Opin Pharmacol. 2021 Oct;60:315-330. doi: 10.1016/j.coph.2021.08.005. Epub 2021 Sep 11.PMID: 34520942
8. Enhancement of Neuroblastoma NK-Cell-Mediated Lysis through NF-κB p65 Subunit-Induced Expression of FAS and PVR, the Loss of Which Is Associated with Poor Patient Outcome.
Brandetti E, Focaccetti C, Pezzolo A, Ognibene M, Folgiero V, Cotugno N, Benvenuto M, Palma P, Manzari V, Rossi P, Fruci D, Bei R, **Cifaldi L***. Cancers (Basel). 2021 Aug 29;13(17):4368. doi: 10.3390/cancers13174368.PMID: 34503178
9. Virological and immunological features of SARS-COV-2 infected children with distinct symptomatology.
Cotugno N, Ruggiero A, Pascucci GR, Bonfante F, Petrara MR, Pighi C, **Cifaldi L**, Zangari P, Bernardi S, Corsi L, Santilli V, Manno EC, Amodio D, Linardos G, Piccioni L, Barbieri MA, Perrotta D, Campana A, Donà D, Giaquinto C; CACTUS Study Team; Concato C, Brodin P, Rossi P, De Rossi A, Palma P. Pediatr Allergy Immunol. 2021 Nov;32(8):1833-1842. doi: 10.1111/pai.13585. Epub 2021 Jul 16.PMID: 34174102

10. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFN γ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M, Sorino C, Caruana I, Weber G, Camera A, **Cifaldi L**, De Angelis B, Del Bufalo F, Vitale A, Goffredo BM, De Vito R, Fruci D, Quintarelli C, Fanciulli M, Locatelli F, Folgiero V. J Immunother Cancer. 2021 Mar;9(3):e001502. doi: 10.1136/jitc-2020-001502.PMID: 33737337
11. The immune system view of the coronavirus SARS-CoV-2.
Celardo I, Pace L, **Cifaldi L**, Gaudio C, Barnaba V. Biol Direct. 2020 Dec 29;15(1):30. doi: 10.1186/s13062-020-00283-2.PMID: 33371901
12. Nutlin-3a Enhances Natural Killer Cell-Mediated Killing of Neuroblastoma by Restoring p53-Dependent Expression of Ligands for NKG2D and DNAM-1 Receptors.
Veneziani I, Infante P, Ferretti E, Melaiu O, Battistelli C, Lucarini V, Compagnone M, Nicoletti C, Castellano A, Petrini S, Ognibene M, Pezzolo A, Di Marcotullio L, Bei R, Moretta L, Pistoia V, Fruci D, Barnaba V, Locatelli F, **Cifaldi L***. Cancer Immunol Res. 2021 Feb;9(2):170-183. doi: 10.1158/2326-6066.CIR-20-0313. Epub 2020 Dec 10.PMID: 33303573
13. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.
Melaiu O, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, Boldrini R, **Cifaldi L**, Castellano A, Furlanello C, Barnaba V, Locatelli F, Fruci D. Nat Commun. 2020 Nov 25;11(1):5992. doi: 10.1038/s41467-020-19781-y.PMID: 33239635
14. PIGF Immunological Impact during Pregnancy.
Albonici L, Benvenuto M, Focaccetti C, **Cifaldi L**, Miele MT, Limana F, Manzari V, Bei R. Int J Mol Sci. 2020 Nov 18;21(22):8714. doi: 10.3390/ijms21228714.PMID: 33218096
15. *IFNAR2* Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis.
Passarelli C, Civino A, Rossi MN, **Cifaldi L**, Lanari V, Moneta GM, Caiello I, Bracaglia C, Montinaro R, Novelli A, De Benedetti F, Prencipe G. Front Genet. 2020 Sep 18;11:937. doi: 10.3389/fgene.2020.00937. eCollection 2020.PMID: 33193576
16. Polyphenol-Mediated Autophagy in Cancer: Evidence of In Vitro and In Vivo Studies.
Benvenuto M, Albonici L, Focaccetti C, Ciuffa S, Fazi S, **Cifaldi L**, Miele MT, De Maio F, Tresoldi I, Manzari V, Modesti A, Masuelli L, Bei R. Int J Mol Sci. 2020 Sep 10;21(18):6635. doi: 10.3390/ijms21186635.PMID: 32927836
17. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer.
Cifaldi L*, Di Santo J, Olive D. Front Immunol. 2020 Jun 16;11:1132. doi: 10.3389/fimmu.2020.01132. eCollection 2020.PMID: 32612604
18. Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors.
Melaiu O, Lucarini V, **Cifaldi L***, Fruci D. Front Immunol. 2020 Jan 21;10:3038. doi: 10.3389/fimmu.2019.03038. eCollection 2019.PMID: 32038612
19. DNAM-1 Activating Receptor and Its Ligands: How Do Viruses Affect the NK Cell-Mediated Immune Surveillance during the Various Phases of Infection?
Cifaldi L*, Doria M, Cotugno N, Zicari S, Cancrini C, Palma P, Rossi P. Int J Mol Sci. 2019 Jul 30;20(15):3715. doi: 10.3390/ijms20153715.PMID: 31366013
20. The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors.
Veneziani I, Fruci D, Compagnone M, Pistoia V, Rossi P, **Cifaldi L***. Oncotarget. 2019 Mar 15;10(22):2151-2160. doi: 10.18632/oncotarget.26736. eCollection 2019 Mar 15.PMID: 31040907

21. Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer.
Compagnone M, **Cifaldi L**, Fruci D. Hum Immunol. 2019 May;80(5):318-324. doi: 10.1016/j.humimm.2019.02.014. Epub 2019 Feb 27. PMID: 30825518
22. Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.
Boldrini R, De Pasquale MD, Melaiu O, Chierici M, Jurman G, Benedetti MC, Salfi NC, Castellano A, Collini P, Furlanello C, Pistoia V, **Cifaldi L**, Terenziani M, Fruci D. Oncoimmunology. 2018 Dec 13;8(2):e1542245. doi: 10.1080/2162402X.2018.1542245. eCollection 2019. PMID: 30713803
23. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Veneziani I, Brandetti E, Ognibene M, Pezzolo A, Pistoia V, **Cifaldi L***. J Immunol Res. 2018 Apr 1;2018:4972410. doi: 10.1155/2018/4972410. eCollection 2018. PMID: 29805983
24. Identification of GAD65 AA 114-122 reactive 'memory-like' NK cells in newly diagnosed Type 1 diabetic patients by HLA-class I pentamers.
Perri V, Giancchetti E, **Cifaldi L**, Pellegrino M, Giorda E, Andreani M, Cappa M, Fierabracci A. PLoS One. 2017 Dec 13;12(12):e0189615. doi: 10.1371/journal.pone.0189615. eCollection 2017. PMID: 29236750
25. Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.
Cifaldi L*, Locatelli F, Marasco E, Moretta L, Pistoia V. Trends Mol Med. 2017 Dec;23(12):1156-1175. doi: 10.1016/j.molmed.2017.10.002. Epub 2017 Nov 10. PMID: 29133133
26. Identification of a Genetic Variation in ERAP1 Aminopeptidase that Prevents Human Cytomegalovirus miR-UL112-5p-Mediated Immuno-evasion.
Romania P, **Cifaldi L**, Pignoloni B, Starc N, D'Alicandro V, Melaiu O, Li Pira G, Giorda E, Carrozzo R, Bergvall M, Bergström T, Alfredsson L, Olsson T, Kockum I, Seppälä I, Lehtimäki T, Hurme MA, Hengel H, Santoni A, Cerboni C, Locatelli F, D'Amato M, Fruci D. Cell Rep. 2017 Jul 25;20(4):846-853. doi: 10.1016/j.celrep.2017.06.084. PMID: 28746870
27. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.
Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, **Cifaldi L***. Oncoimmunology. 2017 Apr 20;6(6):e1316439. doi: 10.1080/2162402X.2017.1316439. eCollection 2017. PMID: 28680748
28. NK cell effector functions in a Chédiak-Higashi patient undergoing cord blood transplantation: Effects of in vitro treatment with IL-2.
Cifaldi L*, Pinto RM, Rana I, Caniglia M, Angioni A, Petrocchi S, Cancrini C, Corsi L, Palumbo G, Zingoni A, Gismondi A, Rossi P, Santoni A, Cerboni C. Immunol Lett. 2016 Dec;180:46-53. doi: 10.1016/j.imlet.2016.10.009. Epub 2016 Nov 2. PMID: 27816481
29. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome.
Cifaldi L, Prencipe G, Caiello I, Bracaglia C, Locatelli F, De Benedetti F, Strippoli R. Arthritis Rheumatol. 2015 Nov;67(11):3037-46. doi: 10.1002/art.39295. PMID: 26251193
30. TIM-3/Gal-9 interaction induces IFN γ -dependent IDO1 expression in acute myeloid leukemia blast cells.
Folgiere V, **Cifaldi L**, Li Pira G, Goffredo BM, Vinti L, Locatelli F. J Hematol Oncol. 2015 Apr 16;8:36. doi: 10.1186/s13045-015-0134-4. PMID: 25886742
31. ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors.

Cifaldi L, Romania P, Falco M, Lorenzi S, Meazza R, Petrini S, Andreani M, Pende D, Locatelli F, Fruci D. Cancer Res. 2015 Mar 1;75(5):824-34. doi: 10.1158/0008-5472.CAN-14-1643. Epub 2015 Jan 15.PMID: 25592150

32. T and NK cells: two sides of tumor immunoevasion.

Fruci D, Lo Monaco E, **Cifaldi L**, Locatelli F, Tremante E, Benevolo M, Giacomini P. J Transl Med. 2013 Feb 4;11:30. doi: 10.1186/1479-5876-11-30.PMID: 23379575

33. IRF1 and NF- κ B restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.

Lorenzi S, Forloni M, **Cifaldi L**, Antonucci C, Citti A, Boldrini R, Pezzullo M, Castellano A, Russo V, van der Bruggen P, Giacomini P, Locatelli F, Fruci D. PLoS One. 2012;7(10):e46928. doi: 10.1371/journal.pone.0046928. Epub 2012 Oct 5.PMID: 23071666

34. Role of endoplasmic reticulum aminopeptidases in health and disease: from infection to cancer.

Cifaldi L, Romania P, Lorenzi S, Locatelli F, Fruci D. Int J Mol Sci. 2012;13(7):8338-8352. doi: 10.3390/ijms13078338. Epub 2012 Jul 4.PMID: 22942706

35. ERAAP modulation: A possible novel strategy for cancer immunotherapy?

Fruci D, Locatelli F, **Cifaldi L**. Oncoimmunology. 2012 Jan 1;1(1):81-82. doi: 10.4161/onci.1.1.17828.PMID: 22720218

36. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis.

Galeano F, Rossetti C, Tomaselli S, **Cifaldi L**, Lezzerini M, Pezzullo M, Boldrini R, Massimi L, Di Rocco CM, Locatelli F, Gallo A. Oncogene. 2013 Feb 21;32(8):998-1009. doi: 10.1038/onc.2012.125. Epub 2012 Apr 23.PMID: 22525274

37. Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma.

Pazzaglia S, **Cifaldi L**, Saran A, Nobili V, Fruci D, Alisi A. Hepatology. 2012 Oct;56(4):1589. doi: 10.1002/hep.25783.PMID: 22505342

38. Major histocompatibility complex class I and tumour immuno-evasion: how to fool T cells and natural killer cells at one time.

Fruci D, Benevolo M, **Cifaldi L**, Lorenzi S, Lo Monaco E, Tremante E, Giacomini P. Curr Oncol. 2012 Feb;19(1):39-41. doi: 10.3747/co.19.945.PMID: 22328841

39. Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing.

Cifaldi L, Lo Monaco E, Forloni M, Giorda E, Lorenzi S, Petrini S, Tremante E, Pende D, Locatelli F, Giacomini P, Fruci D. Cancer Res. 2011 Mar 1;71(5):1597-606. doi: 10.1158/0008-5472.CAN-10-3326. Epub 2011 Jan 20.PMID: 21252114

40. NF- κ B, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells.

Forloni M, Albin S, Limongi MZ, **Cifaldi L**, Boldrini R, Nicotra MR, Giannini G, Natali PG, Giacomini P, Fruci D. Cancer Res. 2010 Feb 1;70(3):916-24. doi: 10.1158/0008-5472.CAN-09-2582. Epub 2010 Jan 26.PMID: 20103633

41. HLA-E and the origin of immunogenic self HLA epitopes.

Lo Monaco E, Tremante E, **Cifaldi L**, Fruci D, Giacomini P. Mol Immunol. 2010 May;47(9):1661-2; author reply 1163-4. doi: 10.1016/j.molimm.2009.12.018. Epub 2010 Jan 22.PMID: 20096934

42. CD56highCD16-CD62L- NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses.
Carbone T, Nasorri F, Pennino D, Eyerich K, Foerster S, **Cifaldi L**, Traidl-Hoffman C, Behrendt H, Cavani A. J Immunol. 2010 Jan 15;184(2):1102-10. doi: 10.4049/jimmunol.0902518. Epub 2009 Dec 11. PMID: 20008290
43. Chronic eczema in a patient with Leukocyte Adhesion Deficiency (LAD) type I.
Eyerich K, **Cifaldi L**, Notarangelo LD, Porta F, Notarangelo L, Mazzolari E, Fiorini M, Paradisi A, Cavani A. Eur J Dermatol. 2009 Jan-Feb;19(1):78-9. doi: 10.1684/ejd.2008.0552. PMID: 19171538
44. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM.
Fontana L, Fiori ME, Albini S, **Cifaldi L**, Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P, Peschle C, Fruci D. PLoS One. 2008 May 21;3(5):e2236. doi: 10.1371/journal.pone.0002236. PMID: 18493594
45. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect.
Gismondi A, **Cifaldi L**, Mazza C, Gilliani S, Parolini S, Morrone S, Jacobelli J, Bandiera E, Notarangelo L, Santoni A. Blood. 2004 Jul 15;104(2):436-43. doi: 10.1182/blood-2003-07-2621. Epub 2004 Mar 4. PMID: 15001467
46. Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration.
Gismondi A, Jacobelli J, Strippoli R, Mainiero F, Soriani A, **Cifaldi L**, Piccoli M, Frati L, Santoni A. J Immunol. 2003 Mar 15;170(6):3065-73. doi: 10.4049/jimmunol.170.6.3065. PMID: 12626562
47. Interleukin 12-activated lymphocytes influence tumor genetic programs.
Cavallo F, Quaglino E, **Cifaldi L**, Di Carlo E, André A, Bernabei P, Musiani P, Forni G, Calogero RA. Cancer Res. 2001 Apr 15;61(8):3518-23. PMID: 11309316
48. A light, nontoxic interleukin 12 protocol inhibits HER-2/neu mammary carcinogenesis in BALB/c transgenic mice with established hyperplasia.
Cifaldi L, Quaglino E, Di Carlo E, Musiani P, Spadaro M, Lollini PL, Wolf S, Boggio K, Forni G, Cavallo F. Cancer Res. 2001 Apr 1;61(7):2809-12. PMID: 11306448

Roma lì, 16 marzo 2023

Loredana Concetta Cifaldi